Polaris Chemicals：2013-08-23
Metastatic breast cancer—breast cancer that has spread from the breast to other parts of the body—is the most common invasive cancer in women
Polaris Chemicals：2013-08-23
Cardiac toxicity: Lapatinib has been associated with reports of decreases in LVEF. Lapatinib has not been evaluated in patients with symptomatic cardiac failure. Caution should be taken if
Polaris Chemicals：2013-08-23
Lapatinib is an orally administered small molecule that inhibits the tyrosine kinase components of the HER1
Polaris Chemicals：2013-08-23
The combination’s (dual) targeting of the same HER2 receptor at different points – ‘above’ and ‘below’ the cell membrane (vertical) – is known as vertical dual blockade
Polaris Chemicals：2013-08-23
GlaxoSmithKline announced today that the European Commission has granted an additional indication for Tyverb™ (lapatinib) to be used in combination with trastuzumab. This combination is indicated
